Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opus Genetics (IRD) Current Assets (2019 - 2026)

Opus Genetics has reported Current Assets over the past 13 years, most recently at $66.6 million for Q1 2026.

  • Quarterly Current Assets rose 38.96% to $66.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $66.6 million through Mar 2026, up 38.96% year-over-year, with the annual reading at $50.0 million for FY2025, 36.69% up from the prior year.
  • Current Assets was $66.6 million for Q1 2026 at Opus Genetics, up from $50.0 million in the prior quarter.
  • Over five years, Current Assets peaked at $66.6 million in Q1 2026 and troughed at $14.6 million in Q3 2022.
  • The 5-year median for Current Assets is $44.8 million (2024), against an average of $41.9 million.
  • Year-over-year, Current Assets plummeted 37.22% in 2022 and then soared 272.14% in 2023.
  • A 5-year view of Current Assets shows it stood at $49.0 million in 2022, then grew by 10.13% to $53.9 million in 2023, then tumbled by 32.14% to $36.6 million in 2024, then soared by 36.69% to $50.0 million in 2025, then soared by 33.08% to $66.6 million in 2026.
  • Per Business Quant, the three most recent readings for IRD's Current Assets are $66.6 million (Q1 2026), $50.0 million (Q4 2025), and $35.9 million (Q3 2025).